The 2015 Symposium of Animal Vaccine Development Center

Development of inactivated Actinobacillus pleuropneumoniae vaccine

JC Hung, ZY Yang, CS Chang, KM Huang, JH Lin, ZW Chen, HH Wu

In this study, the Actinobacillus pleuropneumoniae (APP) bacterin was developed to test the efficacy. The bacterin passed the safety test in mice. Injecting intraperitoneally virulent strains of APP as challenge test in mice, the protective titers were 22.4, 10.0, 43.7, and 22.6, respectively. When applying intratracheally the virulent strains of APP as challenge test in pigs, the control pigs all dead, and immunized pigs all survived and recovered. The field trials of APP bacterin showed that this bacterin can effectively prevent the disease caused by APP.